Halia CEO, David Bearss, on Challenges Posed by FDA Project Optimus
September 5, 2024
Halia Therapeutics’ CEO, David Bearss, recently discussed the FDA’s Project Optimus in The Wall Street Journal. These new regulations pose significant challenges for smaller biopharma companies like Halia. They risk driving innovation overseas due to higher costs and longer timelines. Halia remains, however, committed to identifying the most effective, lowest doses in early trials to deliver safe and potent treatments to patients.
Recent News
- Intermountain Health Announces New Children’s Health President and Expands Leadership Role for Hospital President to Build on Legacy of Pediatric Excellence
- Seek Labs Unveils BioSeeker™
- Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology
- Purgo Scientific Appoints Veteran MedTech Leader as Chief Executive Officer
- Quansys Biosciences Launches Q-View™ Imager Plus: Delivering Reproducible, high-impact ELISA Data with Ease
- Improving Women’s Health: MobileODT Joins Liger Medical